Home Alzheimer’s Disease Patients with Cisplatin-ineligible mUC and High PD-L1 Expression Experience Clinical Benefit With...

Patients with Cisplatin-ineligible mUC and High PD-L1 Expression Experience Clinical Benefit With Atezolizumab

Using the single-agent atezolizumab (Tecentriq) plus chemotherapy versus chemotherapy alone to treat patients in the front-line setting with cisplatin-ineligible IC2/3 advanced or metastatic urothelial carcinoma (mUC) revealed an additional clinical benefit, according to data presented at the 2021 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.1

The exploratory analysis of the phase 3 IMvigor 130 trial (NCT02807636) suggests that PD-L1 scoring of these patients can better identify patients who will benefit from the treatment.

In the primary analysis of IMvigor 130 trial, interim overall survival (OS) data for atezolizumab monotherapy could not be formally tested but favorable efficacy was seen in patients with IC2/3 mUC at a median of 15.7 months (95% CI, 13.1-17.8).2 Moreover, this benefit was initially seen in patients with mUC regardless of cisplatin…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments